Go Pro
→ I've seen this movie before (last time: 17,556%) (From Crypto 101 Media) (Ad)tc pixel
NASDAQ:PPCB

Propanc Biopharma Q4 2026 Earnings Report

Propanc Biopharma logo
$0.53 -0.10 (-15.37%)
Closing price 04:00 PM Eastern
Extended Trading
$0.53 -0.01 (-1.20%)
As of 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Propanc Biopharma EPS Results

Actual EPS
$6.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Propanc Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Propanc Biopharma Announcement Details

Quarter
Q4 2026
Date
9/25/2026
Time
After Market Closes
Conference Call Date
Friday, September 25, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Propanc Biopharma's Q4 2026 Annual reportAnnual report
(10-K)

Propanc Biopharma Earnings Headlines

Propanc Biopharma (NASDAQ:PPCB) Releases Earnings Results
September 27 at 7:11 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31055214
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366329/0/en/propanc-biopharma-highlights-differentiated-prp-pancreatic-cancer-data-versus-emerging-pan-ras-program-eras-0015.html
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.tc pixel
September 28 at 1:00 AM  |  Behind the Markets (Ad)
Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363152/0/en/propanc-biopharma-positions-prp-s-emt-reversal-mechanism-as-a-complementary-backbone-to-emerging-ras-inhibitors-from-revolution-medicines-inc-and-erasca-inc.html
PPCB Advances PRP Toward Phase 1b Study; Trial Start Planned For February 2027
September 9, 2026  |  rttnews.comhttps://www.rttnews.com/3689648/ppcb-advances-prp-toward-phase-1b-study-trial-start-planned-for-february-2027.aspx
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358655/0/en/propanc-biopharma-to-initiate-world-first-phase-1b-first-in-human-study-of-prp-in-february-2027.html
See More Propanc Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Propanc Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Propanc Biopharma and other key companies, straight to your email.

About Propanc Biopharma

Propanc Biopharma (NASDAQ:PPCB), Inc. is a biotechnology company focused on developing novel treatments for solid tumors. The company’s research centers on the use of proenzymes—precursors to digestive enzymes—as a potential therapeutic approach for targeting cancer cells and limiting tumor growth, recurrence and metastasis.

Propanc’s lead product candidate is PRP, an investigational proenzyme therapy being developed primarily for cancers with a high risk of recurrence, including pancreatic, ovarian and colorectal cancers. The company has described PRP as a formulation intended to act on cancer stem cells and other tumor-related mechanisms; its development remains subject to clinical and regulatory evaluation.

Propanc Biopharma was founded in Australia and has operated as a development-stage biotechnology company serving the global oncology market. The company is led by James Nathanielsz, who has served as chief executive officer and has been involved in advancing its proenzyme-based cancer program. Propanc’s activities have primarily consisted of research, preclinical development and clinical planning rather than commercialized pharmaceutical sales.

View Propanc Biopharma Profile
Earnings Tools